Close
Smartlab Europe
Achema middle east

News

Fujifilm to Build the Largest Cell Culture Biopharmaceutical CDMO Facility in North America

FUJIFILM Corporation has announced the selection of Holly Springs, North Carolina as the location for its new large-scale cell culture production site in the United States. The previously announced investment of more than 200 Billion yen (2 Billion USD)...

Alcami Appoints Patrick D. Walsh as Chairman and Chief Executive Officer

Alcami, a global pharmaceutical contract development and manufacturing organization (CDMO), announced today that its Board of Directors has appointed Patrick D. Walsh as Chairman and Chief Executive Officer, effective immediately. He succeeds Walter J. Kaczmarek III, who is stepping...

RDIF and Stelis Biopharma partner to supply 200 million doses of the Sputnik V vaccine

The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), and Stelis Biopharma Pvt. Ltd., the biopharmaceutical division of Strides, a global pharmaceutical company headquartered in India, have partnered to produce, and supply a minimum of 200 million doses...

Samsung Biologics Unveils Strong Performance and Future Plans at its 10th Annual General Meeting of Shareholders

Samsung Biologics announced a strong year in 2020 as it reported 1 trillion won in target sales within just a decade at its 10th Annual General Meeting (AGM) on March 19th. John Rim, CEO and president of Samsung Biologics, led...

PCR Biosystems launches advanced Bst Polymerase reagents for accelerated DNA and RNA amplification

PCR Biosystems, the UK-based specialists in DNA and RNA analysis, have launched a range of IsoFast™ Bst Polymerase reagents for rapid, robust and sensitive DNA and RNA amplification. Through its nucleic acid strand displacement capabilities, Bst polymerase eliminates the...

Moderna starts Phase I study of new Covid-19 vaccine candidate

Moderna Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the first participants have been dosed in the Phase 2/3 study, called the KidCOVE study, of mRNA-1273, the Company’s vaccine candidate against COVID-19, in children...

AstraZeneca to supply the US with up to half a million additional doses of the potential COVID-19 antibody treatment AZD7442

AstraZeneca has modified an existing agreement with the US Government to supply up to 500,000 additional doses of AZD7442, a long-acting antibody (LAAB) combination which is in late-stage development for the prevention and treatment of COVID-19. Today’s agreement with the...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »